ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 123

Combination with Joint Power Doppler Signals with Anti-Citrullinated Peptide Antibody Predicts Joint Destruction in Rheumatoid Arthritis

Yohei Kirino1, Maasa Hama1, Kaoru Minegishi-Takase1, Yosuke Kunishita1, Daiga Kishimoto1, Ryusuke Yoshimi1, Yukiko Asami1, Atsushi Ihata2, Shigeru Ohno3, Atsuhisa Ueda1, Mitsuhiro Takeno4 and Ishigatsubo Yoshiaki1, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, 3Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 4Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ACPA, Doppler ultrasound, rheumatoid arthritis, synovium and ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Ultrasound

Session Type: Abstract Submissions (ACR)

Background/Purpose ,  Categorizing RA patients who require intensive treatments is highly warranted to optimize the therapy and to avoid overtreatments.  We here evaluated the use of predicting joint destruction with joint power Doppler (PD) signal in musculoskeletal ultrasonography (MSUS).

Methods ,  We performed a retrospective study of 331 RA patients (female n = 280 and male n = 51, mean age 57.9 ± 13.2 y.o) who underwent MSUS from 2002 to 2012.  Correlations of progression of joint destructions in 1,308 2nd and 3rd MCP joints with analysis of PD signals of the same joints, clinical findings, age, and disease duration at the study entry, gender, observation period, ACPA, and RF were analyzed in patient- and joint-based fashions, using univariate and multivariate logistic regression analyses and generalized linear mixed model.

Results ,  Patients’ characteristics were as follows: mean disease duration 5.7 ± 7.5 years, observation period 4.6 ± 2.6 years, RF positivity 79.9%, ACPA positivity 76.4%. PD positive 2nd and 3rd joints showed higher rate of joint destruction, especially in ACPA positive patients. Moreover, PD positive joints in ACPA positive patients showed joint destruction even in joints without swelling.  Multivariate analysis determined PD, SJ, observation period, and ACPA as independent risks for joint destruction.

Conclusion ,  PD, SJ, and ACPA are independent predictors for the joint destruction of 2nd and 3rd MCPs in RA. Progression of joint destruction was maximal in PD positive joints in ACPA positive patients, raising the possibility that RA patients are categorized by MSUS findings.


Disclosure:

Y. Kirino,
None;

M. Hama,
None;

K. Minegishi-Takase,
None;

Y. Kunishita,
None;

D. Kishimoto,
None;

R. Yoshimi,
None;

Y. Asami,
None;

A. Ihata,

Janssen Pharmaceutica Product, L.P.,

2,

Astellas,

2,

Eisai,

2,

Santen,

2,

Abbvie,

2,

Bristol-Myers Squibb,

2,

Kaken,

2,

Chugai,

2,

TAP Pharmaceuticals Inc.,

2;

S. Ohno,
None;

A. Ueda,
None;

M. Takeno,
None;

I. Yoshiaki,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/combination-with-joint-power-doppler-signals-with-anti-citrullinated-peptide-antibody-predicts-joint-destruction-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology